Retrospective Cohort Study of Certolizumab Pegol (Cimzia®) and Other Subcutaneous Anti-Tumour Necrosis Factor-Alpha Drugs in Rheumatoid Arthritis to Explore Usage Patterns and Clinical Outcomes in daily clinical practice in the United KingdomFirst published 11/01/2013 Last updated 02/04/2024 EU PAS number: EUPAS3357StudyPlannedDownload as PDF